Easywell Biomedicals, Inc. (TPEX:1799)
Taiwan · Delayed Price · Currency is TWD 33.50
+0.30 (0.90%)
May 29, 2026, 12:53 PM CST
Easywell Biomedicals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 682.56 | 597.41 | 540.44 | 271.63 | 178.9 | 197.28 | |
Revenue Growth (YoY) | 10.35% | 10.54% | 98.96% | 51.84% | -9.32% | -26.29% |
Cost of Revenue | 362.39 | 317.11 | 241.04 | 100.91 | 102.58 | 146.85 |
Gross Profit | 320.18 | 280.31 | 299.4 | 170.72 | 76.31 | 50.43 |
Selling, General & Admin | 128.76 | 113.02 | 94.88 | 61.96 | 28.16 | 24.15 |
Research & Development | 239.93 | 237.14 | 274.33 | 271.5 | 209.41 | 238.14 |
Operating Expenses | 363.82 | 347.51 | 374.19 | 333.46 | 237.57 | 262.29 |
Operating Income | -43.65 | -67.2 | -74.79 | -162.74 | -161.26 | -211.86 |
Interest Expense | -20.56 | -22.48 | -21.16 | -19.26 | -17.25 | -16.08 |
Interest & Investment Income | 3.29 | 2.94 | 4.94 | 3.42 | 2.18 | 1.18 |
Currency Exchange Gain (Loss) | 1.23 | 1.23 | 2.28 | 7.5 | 7.53 | -1.13 |
Other Non Operating Income (Expenses) | 6.83 | 9.72 | 0.34 | 1.17 | 0.46 | 57.99 |
EBT Excluding Unusual Items | -52.86 | -75.79 | -88.39 | -169.91 | -168.34 | -169.91 |
Gain (Loss) on Sale of Investments | 0.43 | 0.43 | 0.16 | - | 0.07 | 0.01 |
Gain (Loss) on Sale of Assets | 0.18 | 0.18 | 0.03 | - | - | 0.24 |
Other Unusual Items | - | - | -0.09 | - | - | - |
Pretax Income | -52.25 | -75.18 | -88.29 | -169.91 | -168.28 | -169.66 |
Income Tax Expense | 0.15 | 0.3 | 0.16 | 0.26 | 0.12 | 0.85 |
Earnings From Continuing Operations | -52.4 | -75.48 | -88.44 | -170.17 | -168.39 | -170.51 |
Net Income to Company | -52.4 | -75.48 | -88.44 | -170.17 | -168.39 | -170.51 |
Minority Interest in Earnings | 0.27 | 2.34 | -9.02 | 25.35 | 7.39 | 20.12 |
Net Income | -52.13 | -73.14 | -97.47 | -144.82 | -161 | -150.39 |
Net Income to Common | -52.13 | -73.14 | -97.47 | -144.82 | -161 | -150.39 |
Shares Outstanding (Basic) | 125 | 124 | 120 | 114 | 114 | 106 |
Shares Outstanding (Diluted) | 125 | 124 | 120 | 114 | 114 | 106 |
Shares Change (YoY) | 2.74% | 3.02% | 5.03% | 0.05% | 7.48% | 14.08% |
EPS (Basic) | -0.42 | -0.59 | -0.81 | -1.27 | -1.41 | -1.41 |
EPS (Diluted) | -0.42 | -0.59 | -0.81 | -1.27 | -1.41 | -1.41 |
Free Cash Flow | 148.21 | 109.37 | -171.53 | -169.17 | -60.99 | -136.02 |
Free Cash Flow Per Share | 1.19 | 0.88 | -1.43 | -1.48 | -0.53 | -1.28 |
Gross Margin | 46.91% | 46.92% | 55.40% | 62.85% | 42.66% | 25.56% |
Operating Margin | -6.40% | -11.25% | -13.84% | -59.91% | -90.14% | -107.39% |
Profit Margin | -7.64% | -12.24% | -18.04% | -53.31% | -90.00% | -76.23% |
Free Cash Flow Margin | 21.71% | 18.31% | -31.74% | -62.28% | -34.09% | -68.95% |
EBITDA | 26.47 | -2.48 | -22.19 | -121.01 | -116 | -160.42 |
EBITDA Margin | 3.88% | -0.41% | -4.11% | -44.55% | -64.84% | -81.32% |
D&A For EBITDA | 70.11 | 64.72 | 52.6 | 41.73 | 45.26 | 51.45 |
EBIT | -43.65 | -67.2 | -74.79 | -162.74 | -161.26 | -211.86 |
EBIT Margin | -6.40% | -11.25% | -13.84% | -59.91% | -90.14% | -107.39% |